Work

Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin

Year: 2015

Type: review

Source: Current Opinion in Genetics & Development

DOI: 10.1016/j.gde.2015.08.001

Authors: Daniel E Bauer, Stuart H Orkin

Institutions: Boston Children's Hospital, Harvard University, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Howard Hughes Medical Institute

Language: English

Topic: Hemoglobinopathies and Related Disorders

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Howard Hughes Medical Institute, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases

Awards: A CENTER OF MOLECULAR DEVELOPMENTAL HEMATOPOIESIS, DEVELOPMENTAL BIOLOGY OF HUMAN ERYTHROPOIESIS, Molecular Analysis of Normal and Thalassemic DNA, G5138542659, Epigenetic regulation of BCL11A in the hemoglobin switch, Translational and clinical studies targeting y-globin modulation, G9000124058

OpenAlex ID: W2185201235

FWCI: 1.763

Cites: 75

Cited by: 147

Related to: 10